Skip to content

Research collaborationStardots & BrainZell

Cross-AI

Connecting human measurements with neural organoid research

Explore the research
Cross-AI research collaboration
  1. Human measurements
  2. Shared AI research
  3. Neural organoid research
Conceptual illustration — not research data

Cross-AI is the research collaboration between Stardots and BrainZell, investigating how drug responses in patient-derived neural organoids relate to measurable effects in people. Combining complementary technologies and the AI expertise of both companies, the partners aim to connect laboratory research with human measurements.

Two perspectives on drug response

BrainZell develops patient-derived neural organoid models and assays for investigating neural biology and drug responses. Stardots’ Psilmi research platform combines synchronised measurements of pupil dynamics, eye movements and cognitive performance. Together, these cellular and human perspectives offer a way to investigate relationships across different types of measurement.

BrainZell will draw on Stardots’ existing Psilmi platform as a human measurement reference within its organoid research workflow. Stardots contributes its platform, human-measurement and data-translation expertise; BrainZell contributes organoid models, electrophysiology and experimental capabilities.

Human measurements

Stardots · Psilmi

Pupil dynamics, eye movements and cognitive performance

Shared AI research

Neural organoid research

BrainZell

Organoid models, electrophysiology and experimental capabilities

Relationships under investigationInvestigating relationships across human and cellular measurements.

Shared AI research

The name Cross-AI reflects cross-scale artificial intelligence: using AI to investigate relationships between human-level measurements and cellular-level activity in neural organoid models. Both companies’ AI teams will work together to relate Psilmi’s neuro-ocular and cognitive measurements to responses in BrainZell’s high-throughput organoid arrays, which are used to explore biological targets and test compounds. The aim is to learn relationships across spatial and temporal scales, supporting research translation in both directions.

Over time, the partners aim to explore whether linked cellular and human measurements could support drug discovery and candidate assessment, help characterise differences between research participants, and inform treatment-response measurement. These are research ambitions, not demonstrated outcomes.

A proposed focus on bipolar disorder

Bipolar disorder is the proposed initial research focus. The partners aim to investigate whether patterns observed in neural organoid experiments can be related to human measurements collected through Psilmi. This work would explore potential links between laboratory drug responses and treatment-related changes in people; those links remain research questions, not validated predictors of treatment response.

Responsible research and validation

The combined human–organoid approach is at an early research stage. Any predictive or clinical application would require further validation and, where applicable, regulatory review. A selected subset of participants could provide matched human and organoid data, subject to the relevant consent, ethics, data-protection and donor-governance review.

Psilmi’s underlying dataset originates from a research project at Uppsala University, which Stardots accesses through collaboration with the university. Any use of these data in the programme remains subject to the applicable approvals and governance.

Discuss a research collaboration

Interested in the connection between human measurements, neural organoid research and pharmaceutical development? Contact Stardots to discuss potential research opportunities.

info@stardots.se